FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Sanofi licenses technology for new TB vaccine

  • Email
  • Print
  • Comment
  • Contact Author

Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31 adjuvant and the use of certain fusion proteins. SSI TB vaccine candidates are recombinant protein sub-units, including one currently in a Phase I clinical trial. Results from a previous study showed the SSI TB vaccine technology provided a positive immune response. TB kills two million people a year. 

"This agreement is a milestone for Sanofi Pasteur," said Wayne Pisano, president and CEO of Sanofi Pasteur, which is also working to develop a vaccine against another one of the biggest global infectious disease killers--malaria. "The current medical arsenal is inadequate for fighting tuberculosis."

- read the press release

Related Articles:
New compounds in works for tuberculosis. Report
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Report
New approach to vaccine development. Report

More stories about Malaria   immune system   Vaccine Technology   Sanofi Pasteur   Tuberculosis   Tuberculosis Vaccine  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 21 + 2?
To combat spam, please solve the math question above.